Isonicotinoyl chloride hydrochloride → Hydrochloric Acid

HRID 2382444

反応式

[NH2:1][C@@H:2]1[CH2:6][CH2:5][N:4]([C:7]2[N:15]=[C:14]3[C:10]([N:11]=[CH:12][N:13]3[C@@H:16]3[CH2:20][C@H:19]([NH:21][C:22](=[O:25])[CH2:23][CH3:24])[C@@H:18]([OH:26])[C@H:17]3[OH:27])=[C:9]([NH:28][CH2:29][CH:30]([C:38]3[CH:43]=[CH:42][C:41]([OH:44])=[CH:40][CH:39]=3)[C:31]3[CH:36]=[CH:35][C:34]([OH:37])=[CH:33][CH:32]=3)[N:8]=2)[CH2:3]1.[ClH:45].[C:46]([Cl:54])(=[O:53])[C:47]1[CH:52]=[CH:51][N:50]=[CH:49][CH:48]=1>C1COCC1.CN1C(=O)CCC1>[ClH:54].[ClH:45].[OH:44][C:41]1[CH:42]=[CH:43][C:38]([CH:30]([C:31]2[CH:36]=[CH:35][C:34]([OH:37])=[CH:33][CH:32]=2)[CH2:29][NH:28][C:9]2[N:8]=[C:7]([N:4]3[CH2:5][CH2:6][C@@H:2]([NH:1][C:46](=[O:53])[C:47]4[CH:52]=[CH:51][N:50]=[CH:49][CH:48]=4)[CH2:3]3)[N:15]=[C:14]3[C:10]=2[N:11]=[CH:12][N:13]3[C@@H:16]2[CH2:20][C@H:19]([NH:21][C:22](=[O:25])[CH2:23][CH3:24])[C@@H:18]([OH:26])[C@H:17]2[OH:27])=[CH:39][CH:40]=1

参加物

実験手順

A mixture comprising N-((1S,2R,3S,4R)-4-{2-((R)-3-amino-pyrrolidin-1-yl)-6-[2,2-bis-(4-hydroxy-phenyl)-ethylamino]-purin-9-yl}-2,3-dihydroxy-cyclopentyl)-propionamide (Example 22 step 4) (20 mg, 33 μmol) in THF (0.5 ml) and NMP (0.5 ml) is treated with TEA (13 mg, 0.13 mmol) followed by isonicotinoyl chloride hydrochloride (16 mg, 83 μmol). After stirring at room temperature for 2 hours, the solvent is removed in vacuo and purification by C-18 reverse phase column chromatography eluting with acetonitrile:water:HCl (0.1%) (gradient of 0 to 100% acetonitrile) yields the title compound. (MH+ 708.4)

後処理

customthe solvent is removed in vacuo and purification by C-18 reverse phase column chromatography
washeluting with acetonitrile

出典と根拠

ORDレコード: ord-adb39d173d3d473fb85e1a6db5973e04
出典データセット: uspto-grants-2012_09
DOI: 10.6084/m9.figshare.5104873.v1
特許番号: US08258141B2

反応式

参加物

反応物 2

生成物 2

試薬・触媒・溶媒 2

実験手順

後処理

出典と根拠

関連ノート